Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Vous n'êtes pas connecté
SYDNEY, July 10, 2024. Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients...
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...